Tumor suppressor role of miR-217 in human epithelial ovarian cancer by targeting IGF1R
Authors: Weiyuan Zhang
Jieyan Li
Dongmei Li
Journal: Oncology Reports (2016)
Discipline: CLINICAL MEDICINE
Keywords: microRNA-217; epithelial ovarian cancer; tumorigenesis; metastasis; FIGO stage
Affiliations: Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, P.R. China., Special Education Department of Changchun University, Changchun, Jilin 130022, P.R. China.

Abstract:  Accumulating evidence shows that microRNA-217 (miR-217) is frequently dysregulated in various cancers, and plays crucial roles in tumorigenesis and metastasis; however, the role and underlying molecular mechanism of miR-217 in human epithelial ovarian cancer (EOC) remains unclear. Here, we report that miR-217 expression was downregulated in EOC tissue and inversely correlated with advanced FIGO stage, high histological grading and lymph node metastasis (P&lt;0.01). Function analysis revealed that the ectopic expression of miR-217 in EOC cells inhibited cell proliferation, migration and invasion in vitro, as well as suppressed tumor growth in vivo. Bioinformatics analysis and dual luciferase assays identified insulin-like growth factor 1 receptor (IGF1R) as a direct target of miR-217 in EOC cells. Western blot assay showed that overexpression of miR-217 in EOC cells inhibited IGF1R expression. In addition, downregulation of IGF1R mimicked the tumor-suppressive effects of miR-217 in EOC cells, whereas the reintroduction of IGF1R partially abrogated the suppression effect induced by miR-217 on EOC cells. Collectively, these results demonstrated that miR-217 plays a tumor suppressor role in human epithelial ovarian cancer by directly targeting IGF1R gene, suggesting a new potential therapeutic target in EOC. 

Retracted: No

PubPeer comments:
 Figs 4B, 6D.  Figs 4D, 6B, 7F from [Peng et al (2016)] .  Colored rectangles also aid comparison with Fig 6 from [Wu et al (2015)] .  , 
 Dear Hoya Camphorifolia, Thank you for your comment. Our team will investigate these questions, and reply you as quickly as possible. Best regards , 
 The authors may wish to include Fig 2E in their investigation.  , 
 And Fig 2D, here compared with *[right]* Fig 3A from  miR-137 acts as a tumor suppressor in papillary thyroid carcinoma by targeting CXCL12 ([Dong et al 2016] ) **[retracted]**.  , 
 Retracted [26 September 2022] .  Following the publication of the above paper, a concerned reader drew to the Editors attention that certain of the western blot data shown in Figs. 4B and 6D, and the scratchu2011wound assay data shown in Fig. 2D, were strikingly similar to data that had already appeared in previously published papers written by different authors at different institutes. Furthermore, there appeared to be anomalies associated with the cell invasion assay data portrayed in Fig. 2E. Having considered the issues identified, the Editor of Oncology Reports has decided that this article should be retracted from the Journal on account of the reappearance of previously published data and the uncertainties regarding the data in Fig. 2E. After consulting the authors, they agreed with the Editor s decision that this paper should be retracted. The Editor apologizes to the readership for any inconvenience caused. ,